Aetna announced plans on Thursday, September 27, to sell its Medicare prescription-drug business to WellCare Health Plans, a key step towards gaining regulator approval for its US$67.5 billion merger with CVS.
Although financial terms of the deal weren’t disclosed, in a securities filing, Aetna stated that the “purchase price is not material” to the company. The divestiture of the Medicare Part D to WellCare may help resolve objections to the CVS-Aetna deal from US antitrust regulators.
The company stated in the filing that, “Aetna believes the divestiture is a significant step toward completing the DOJ’s (Department of Justice) review.”
WellCare, a smaller health insurer that’s based in Tampa, Florida, has been using deals to fuel its expansion. The company completed a US$2.5 billion deal for the health insurer Meridian in early September, adding about 1.1 million insurance customers to its base of 4.4 million members.
Full Content: Reuters
Featured News
PepsiCo Sued Over Alleged Price Discrimination Involving Walmart
Jan 19, 2025 by
CPI
Regulators Approve Conditions for Multibillion-Dollar Oil Mergers
Jan 19, 2025 by
CPI
FTC Reaches Settlement with Private Equity Firm Over Antitrust Allegations in Texas
Jan 19, 2025 by
CPI
FTC Raises Antitrust Concerns Over Big Tech’s AI Partnerships
Jan 19, 2025 by
CPI
MultiPlan and Insurers Move to Dismiss Antitrust Allegations Amid Growing Legal Challenges
Jan 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand